CYP26A1 and neoplasm: CYP26A1 has been shown to be expressed at a constitutively higher level in breast adenocarcinomas which can be selectively inhibited, e.g., by use of a RA metabolism blocking agent R116010, demonstrating an anti-tumour effect in ER+ mouse tumours [106].